Search

Tackling Sickle Cell Disease: the need for a European approach

Elvie Ingoli, president of the German association of SCD and thalassemia patients, at the 7th EAPM Presidency Conference in Brussels. Sickle Cell Disease (SCD) is relatively new to many parts of Europe.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Fabienne Lucas, our January Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more